JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Blood

• Publication date

  2006-10-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2006-04-014712PMID 16804112PMCID PMC1895587
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

  2006cited by this paper
• The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor.

  2006cited by this paper
• A gain-of-function mutation of JAK2 in myeloproliferative disorders.

  2005cited by this paper
• GATA1 in normal and malignant hematopoiesis.

  2005cited by this paper
• Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

  2005cited by this paper
• Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.

  2005cited by this paper
• Developmental stage–selective effect of somatically mutated leukemogenic transcription factor GATA1

  2005cited by this paper
• Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

  2005cited by this paper
• Immunoaffinity profiling of tyrosine phosphorylation in cancer cells

  2005cited by this paper
• Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog.

  2005cited by this paper
• JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.

  2005cited by this paper
• Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

  2005cited by this paper
• The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

  2004cited by this paper
• Lnk Inhibits Tpo–mpl Signaling and Tpo-mediated Megakaryocytopoiesis

  2004cited by this paper
• Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome.

  2004cited by this paper
• The role of FLT3 in haematopoietic malignancies

  2003cited by this paper
• Signal transduction by several KIT juxtamembrane domain mutations

  2003cited by this paper
• Biology, clinical, and hematologic features of acute megakaryoblastic leukemia in children

  2003cited by this paper
• Acute Megakaryoblastic Leukaemia: A National Clinical and Biological Study of 53 Adult and Childhood Cases by the Groupe Français d'Hématologie Cellulaire (GFHC)

  2003cited by this paper
• Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.

  2003cited by this paper
• Signal transducer and activator of transcription proteins in leukemias.

  2003cited by this paper
• Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome

  2002cited by this paper
• Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogénétique Hématologique (GFCH).

  2002cited by this paper
• Chromosome 19 abnormalities are commonly seen in AML, M7.

  2002cited by this paper
• Different ploidy levels of megakaryocytes generated from peripheral or cord blood CD34+ cells are correlated with different levels of platelet release.

  2002cited by this paper
• Acute megakaryocytic leukemia in essential thrombocythemia: an unusual evolution?

  2002cited by this paper
• Janus kinase 2 is involved in stromal cell-derived factor-1alpha-induced tyrosine phosphorylation of focal adhesion proteins and migration of hematopoietic progenitor cells.

  2001cited by this paper
• Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia

  2001cited by this paper
• Constitutive activation of STAT transcription factors in acute myelogenous leukemia

  2001cited by this paper
• Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia

  2001cited by this paper
• Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines

  2000cited by this paper
• Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines

  2000cited by this paper
• Congenital acute megakaryoblastic leukemia (M7) with chromosomal t(1;22)(p13;q13) translocation in a set of identical twins.

  1999cited by this paper
• The chemokine SDF‐lα triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway

  1999cited by this paper
• The enigmatic megakaryocyte gradually reveals its secrets.

  1999cited by this paper
• Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

  1999cited by this paper
• Transformation of hematopoietic cell lines to growth‐factor independence and induction of a fatal myelo‐ and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes

  1998cited by this paper
• STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients.

  1996cited by this paper
• A low affinity chimeric human alpha/beta-granulocyte-macrophage colony-stimulating factor receptor induces ligand-dependent proliferation in a murine cell line.

  1994cited by this paper
• Leukemia in Down syndrome: a review.

  1992cited by this paper
• Expression of CD34 and platelet glycoproteins during human megakaryocytic differentiation.

  1992cited by this paper
• The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children.

  1992cited by this paper
• The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains

  1991cited by this paper
• Improved methods for building protein models in electron density maps and the location of errors in these models.

  1991cited by this paper
• In vitro establishment and characterization of a human megakaryoblastic cell line.

  1990cited by this paper
• Cytogenetic findings in adult acute leukemia and myeloproliferative disorders with an involvement of megakaryocyte lineage

  1990cited by this paper
• Myeloproliferative disorders terminating in acute megakaryoblastic leukemia with chromosome 3q26 abnormality

  1987cited by this paper
• Megakaryoblastic leukemia in an infant: Establishment of a megakaryocytic tumor cell line in athymic nude mice

  1986cited by this paper
• Immunological study of in vitro maturation of human megakaryocytes

  1984cited by this paper

• Therapeutic advances of targeting receptor tyrosine kinases in cancer

  2024cites this paper
• Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis

  2022cites this paper
• Germline Variants Associated with Nasopharyngeal Carcinoma Predisposition Identified through Whole-Exome Sequencing

  2022cites this paper
• Recurrent germline variant in ATM associated with familial myeloproliferative neoplasms

  2022cites this paper
• The Mutational Landscape of Myeloid Leukaemia in Down Syndrome

  2021cites this paper
• Molecular Mechanisms of the Genetic Predisposition to Acute Megakaryoblastic Leukemia in Infants With Down Syndrome

  2021cites this paper
• Activating mutations of the gp130/JAK/STAT pathway in human diseases.

  2019cites this paper
• Roles of T875N somatic mutation in the activity, structural stability of JAK2 and the transformation of OCI-AML3 cells.

  2019cites this paper
• JAK, an Oncokinase in Hematological Cancer

  2019influential citation
• Essential thrombocytosis attributed to JAK2-T875N germline mutation

  2019cites this paper
• Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations

  2019cites this paper
• Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling.

  2019cites this paper
• Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia

  2019cites this paper
• The changing scenario of non-Down syndrome acute megakaryoblastic leukemia in children.

  2019cites this paper
• “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway

  2018cites this paper
• [Pediatric de novo acute megakaryoblastic leukemia: an affair of complexes].

  2018cites this paper
• BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.

  2018cites this paper
• Cancer stem cells and differentiation therapy

  2017cites this paper
• Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix

  2016cites this paper
• Cinnamic Acid Derivatives as Inhibitors of Oncogenic Protein Kinases--Structure, Mechanisms and Biomedical Effects.

  2016cites this paper
• Effects of Jak2 Type 1 Inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 Mutation-Positive and Bcr-Abl-Positive Cell Lines

  2014cites this paper
• connection Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase

  2014cites this paper
• c-Abl Activates Janus Kinase 2 in Normal Hematopoietic Cells*

  2014cites this paper
• Molecular Pathways Molecular Pathways : Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors

  2014cites this paper
• The SKI proto-oncogene enhances the in vivo repopulation of hematopoietic stem cells and causes myeloproliferative disease

  2014cites this paper
• Functional Characterization of the Kinase and Pseudokinase Domains in the Janus Tyrosine Kinase (JAK) 2

  2014cites this paper
• Hematopoietic Cells c-Abl Activates Janus Kinase 2 in Normal

  2014cites this paper
• JAK2 Tyrosine Kinase Phosphorylates and Is Negatively Regulated by Centrosomal Protein Ninein

  2014cites this paper
• of the Myc and Pim proto-oncogenes requires a functional FERM domain for transformation and for expression The Jak2V617F oncogene associated with myeloproliferative diseases

  2013cites this paper
• leukemia Identification of somatic JAK1 mutations in patients with acute myeloid

  2013cites this paper
• Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.

  2013cites this paper
• JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells

  2013cites this paper
• Redox regulation of Janus kinase

  2013cites this paper
• Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F

  2013cites this paper
• Understanding the Molecular and Functional Mechanisms that Underlie Pharamcogenomics-Based Therapy

  2012cites this paper
• Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models

  2012cites this paper
• Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection.

  2012cites this paper
• Investigation and analysis of single nucleotide polymorphisms in Janus kinase/signal transducer and activator of transcription genes with leukemia

  2012cites this paper
• Title Comparison of mutated JAK 2 and ABL 1 as oncogenes and drug targets in myeloproliferative disorders

  2012cites this paper
• The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia

  2012cites this paper
• JAK2 inhibition for the treatment of hematologic and solid malignancies

  2012cites this paper
• Regulation of JAKs: Insights gleaned from the functional protein domains

  2012cites this paper
• Comparison of mutated JAK2 and ABL1 as oncogenes and drug targets in myeloproliferative disorders

  2012cites this paper
• Characterization of structure-function correlations of novel Jak2 small molecule inhibitors and their mechanisms of action

  2011cites this paper
• Virtual screening and synthesis of quinazolines as novel JAK2 inhibitors.

  2011cites this paper
• Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.

  2011cites this paper
• A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination.

  2011cites this paper
• Update on JAK2 inhibitors in myeloproliferative neoplasm

  2011cites this paper
• Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.

  2011cites this paper
• Differential biological activity of disease‐associated JAK2 mutants

  2011cites this paper
• Modification of CellSensor irf1-bla TF-1 and irf1-bla HEL Assays for Direct Comparison of Wild-Type JAK2 and JAK2 V617F Inhibition

  2011cites this paper
• A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.

  2011cites this paper
• Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells

  2010cites this paper
• Cytokine Receptor Signaling

  2010cites this paper
• The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases

  2010cites this paper
• Inhibition of Deubiquitinase Activity and Ubiquitination of Jak2 Blocks Cytokine Signaling and Induces Tumor Cell Apoptosis

  2010cites this paper
• Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases

  2010cites this paper
• Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells

  2010cites this paper
• Deletions of the transcription factor Ikaros in myeloproliferative neoplasms

  2010cites this paper
• JAK2 V617F Constitutive Activation Requires JH2 Residue F595: A Pseudokinase Domain Target for Specific Inhibitors

  2010cites this paper
• Acute leukemias in children with Down syndrome.

  2010cites this paper
• Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.

  2010cites this paper
• Tyrosines 868, 966, and 972 in the kinase domain of JAK2 are autophosphorylated and required for maximal JAK2 kinase activity.

  2010cites this paper
• Introduction to “Classic” Chronic Myeloproliferative Disorders (CMPDs) — Molecular and Cellular Biology

  2010cites this paper
• Molecular Pathogenesis of Nonchronic Myeloid Leukemia Myeloproliferative Neoplasms

  2010cites this paper
• Characterization of novel Jak2 tyrosine kinase small molecule inhibitors and sites of Jak2 phospho-regulation

  2009cites this paper
• Jak2 inhibitors: Rationale and role as therapeutic agents in hematologic malignancies

  2009cites this paper
• Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models.

  2009cites this paper
• The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model.

  2009cites this paper
• PALEOECOLOGY OF FOREST ENVIRONMENTS THROUGH TIME: EVIDENCE FROM STABLE ISOTOPES OF MAMMALIAN HERBIVORES IN THE NEW WORLD

  2009cites this paper
• STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease.

  2009cites this paper
• Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.

  2009cites this paper
• The role of GATA-1 isoforms in haematopoiesis

  2009cites this paper
• A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms

  2009cites this paper
• Janus kinase mutations.

  2009cites this paper
• SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling

  2009cites this paper
• Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis

  2009cites this paper
• JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.

  2009cites this paper
• Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders

  2008cites this paper
• Activating mutations in human acute megakaryoblastic leukemia.

  2008cites this paper
• Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1

  2008cites this paper
• JAK and MPL mutations in myeloid malignancies

  2008cites this paper
• JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science

  2008cites this paper
• Mining for JAK-STAT mutations in cancer.

  2008cites this paper
• Cooperating gene mutations in acute myeloid leukemia: a review of the literature

  2008cites this paper
• Identification of somatic JAK 1 mutations in patients with acute myeloid leukemia

  2008cites this paper
• The implication of identifying JAK2V617F in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis

  2008cites this paper
• JAK2 mutations other than V617F: a novel mutation and mini review.

  2008cites this paper
• JAK2 and MPL Mutations in Myeloproliferative Neoplasms

  2008cites this paper
• The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.

  2008cites this paper
• JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.

  2008cites this paper
• Acute leukemias in children with Down syndrome.

  2008cites this paper
• Dimerization by a Cytokine Receptor Is Necessary for Constitutive Activation of JAK2V617F*

  2008cites this paper
• Identification of somatic JAK1 mutations in patients with acute myeloid leukemia.

  2008cites this paper
• Myeloproliferative disorders.

  2008cites this paper
• Tandem immunoprecipitation of phosphotyrosine-mass spectrometry (TIPY-MS) indicates C19ORF19 becomes tyrosine-phosphorylated and associated with activated epidermal growth factor receptor.

  2008cites this paper
• The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.

  2008cites this paper
• The JAK kinase inhibitor CP‐690,550 supresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation

  2008cites this paper
• JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

  2008cites this paper
• Murine Models of Hematopoietic Disease: Pathologic Analysis and Characterization

  2008cites this paper